News | June 16, 2023
PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
He is also inducted as a member of the management council and senior management personnel of the company
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Subscribe To Our Newsletter & Stay Updated
